Pluri’s Innovation Across Various Industries: CEO Updates on Recent Achievements & 2024 Goals
28 févr. 2024 07h00 HE
|
Pluri Inc.
Growing pipeline of industry-specific new potential products, services, collaborations and partnerships through PluriAgtech, PluriCDMO, PluriHealth, and PluriFoodRecent achievements include: new...
Step into the Future: Pluri Launches Sustainable Cell-Based Coffee as Countermeasure for Global Coffee Crisis
23 janv. 2024 02h00 HE
|
Pluri Inc.
Pluri to leverage its proprietary 3D technology platform to develop cell-based products for the coffee industry under its new business vertical PluriAgtechThe rapidly growing $130 billion coffee...
Pluri Launches Advanced Global Cell Therapy Contract Development and Manufacturing Organization
08 janv. 2024 07h00 HE
|
Pluri Inc.
Pluri Launches Advanced Global Cell Therapy Contract Development and Manufacturing Organization
Pluri and Bar-Ilan University to Develop PLX Cells for the Treatment of Cocaine Addiction
21 déc. 2023 07h00 HE
|
Pluri Inc.
Agreement signed following positive pre-clinical data demonstrating a one-time treatment with PLX-PAD significantly increased neurogenesis, offering immediate, long-term therapeutic effect in treating...
Pluri’s PLX-R18 Increases Blood Cell Counts and Reduces Need for Transfusions in a Phase I Study: Results Published in Nature Bone Marrow Transplantation
16 août 2023 07h00 HE
|
Pluri Inc.
Results support the development of PLX-R18 for hematologic acute radiation syndrome (H-ARS), currently under a $4.2 million contract with the U.S. National Institutes of HealthPLX-R18 has the...
Pluri Announces Appointment of Entrepreneur Lorne Abony to Board of Directors
13 juil. 2023 02h00 HE
|
Pluri Inc.
HAIFA, Israel, July 13, 2023 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), a leading biotech company that transforms cells into solutions that promote...
U.S. National Institutes of Health to Fund $4.2 Million Contract to Advance Development of Pluri’s PLX-R18 in Conjunction with U.S. DoD as a Medical Countermeasure for Hematopoietic Acute Radiation Syndrome
11 juil. 2023 02h00 HE
|
Pluri Inc.
Pluri's cell therapy is designed to be the first in class, effective treatment for ionizing radiation poisoning in the event of a large-scale nuclear incident.The work specified by the contract is...
Cell Manufacturing Pioneer, Pluri Inc., Unveils PluriMatrix: a Breakthrough System for Unprecedented Industrial Scale Production of Cell-Based Products
27 avr. 2023 07h00 HE
|
Pluri Inc.
Breakthrough system substantially increases cell production, with the potential to reach much higher productivity driven by platform’s significant scalability Flexible, industrial scale cell...
Israel’s Ministry of Labor Names Pluri as Winner of the 2022 Egalitarian Employment Award for its Commitment to Gender Diversity and Pay Equity
13 mars 2023 08h00 HE
|
Pluri Inc.
HAIFA, Israel, March 13, 2023 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”) (formerly known as Pluristem Therapeutics, Inc.), a leading biotechnology company,...
Pluri CEO Issues Letter to Shareholders Summarizing the Strategy Change and Progress in 2022 and Announcing Food Tech Joint Venture Proof of Concept
22 déc. 2022 07h00 HE
|
Pluri Inc.
Milestones over the last year include launch of new Company strategy, joint venture with Tnuva Group in the field of cultivated meat and additional biologics technology partnership;Joint venture with...